Michael Makris Shares 2 Fascinating Lessons from Hemophilia Care in Japan
Michael Makris, Emeritus Professor of Haemostasis and Thrombosis at the University of Sheffield, UK. Editor-in-Chief of Research and Practice in Thrombosis and Haemostasis, shared a post on LinkedIn:
”Two surprising facts I learnt about hemophilia care from my visit to Japan:
1. There are 7,000 patients with hemophilia A or B in Japan. They receive their care from 800 medical facilities. There are around 100 hemophilia treatment centres, but not all patients are seen here. Many patients have their hemophilia care provided by their local General Practitioners.
I find it difficult to understand how modern hemophilia care can be adequately provided outside hemophilia centres.
2. A number of consultant hematologists in Japan actually have hemophilia themselves. At dinner one evening I was sitting at a table with five consultant hematologists with hemophilia.”
During a recent visit to Japan, Michael Makris, Emeritus Professor of Haemostasis and Thrombosis at the University of Sheffield, UK. Editor-in-Chief of Research and Practice in Thrombosis and Haemostasis, observed two surprising aspects of hemophilia care in the country.
Firstly, among Japan’s 7,000 patients with hemophilia A or B, care is delivered across 800 medical facilities, with only around 100 designated hemophilia treatment centers.
Remarkably, many patients are managed by local General Practitioners rather than specialized centers—a model that raises questions about maintaining comprehensive, modern standards of care.
Secondly, Professor Michael Makris encountered a uniquely personal dimension of the medical community: several consultant hematologists in Japan live with hemophilia themselves.
In one memorable instance, he shared a dinner table with five consultant hematologists who have hemophilia—a testament to resilience and dedication within the field.
These reflections highlight distinctive features of Japan’s approach to hemophilia care, prompting consideration of care models and patient-professional dynamics worldwide.
More interesting facts about hemophilia featured in Hemostasis Today.
-
Sep 7, 2025, 16:14Paddy Barret on Thin Cap Fibroatheroma's Outcomes
-
Sep 6, 2025, 14:04Chokri Ben Lamine – VTE Prophylaxis in Pregnancy (ASH 2018 Guidelines)
-
Sep 6, 2025, 13:48The Body Explained on Blood Clotting Pathways
-
Sep 5, 2025, 14:06Thrombosis Update: VTE Death Rate 3X Higher in Los Angeles Jails Than General Population
-
Sep 5, 2025, 10:59New Study Featured by Rare Disease Advisor Reveals Quality-of-Life Challenges in Hemophilia
-
Sep 6, 2025, 16:43Khaled Musallam: de-LIGHT Study on Use of Lifetime Anemia and Iron Control Index (LAICI) in Thalassemia Treatment
-
Sep 6, 2025, 15:06Managing Gynecologic Bleeding in Anticoagulated Patients: Toolkit Co-Authored by Divyaswathi Citla Sridhar
-
Sep 6, 2025, 14:30Mattia Galli on Whether Reduction in MACE Really Depicts Situation in Spontaneous MI or Death post-PCI
-
Sep 6, 2025, 13:55Patrick Cieran Gallogly and Colleagues on Atypical Symptoms in TIA and Minor Stroke
-
Sep 6, 2025, 13:37Unfractionated Heparin Dosing in ECMO: A Systematic Review and Meta-Analysis
-
Sep 2, 2025, 13:53Cost-Effective Strategies to Reduce Anaemia Highlighted in The Lancet Haematology
-
Sep 2, 2025, 13:04Ischemic Stroke or TIA Linked to Higher Femoral Fracture Risk
-
Sep 2, 2025, 12:51Treatment of Deep Brain AVMs Tied to Increased Hemorrhagic Stroke Risk
-
Aug 29, 2025, 09:03Vasculearn Network: New 2025 High Blood Pressure Guidelines Are Here
-
Aug 18, 2025, 23:56Dr. Arun V. J Invites You to His Lecture on ‘AI and Data Sciences in Transfusion Medicine’ at the AI in Healthcare Conclave. Register now!
-
Sep 7, 2025, 16:01Congratulations to Bart Loeys on Receiving Doctor Honoris Causa!
-
Sep 6, 2025, 14:09Erin VanDyke: Shifting Attention Upstream in VTE Care Through NBCA Centers of Excellence
-
Sep 6, 2025, 12:02Caitlin Raymond on Kairos in Medicine: How Curiosity Sustains Physicians and Prevents Burnout
-
Sep 5, 2025, 14:12EAHAD Podcast: Reducing Pain and Distress in Children Receiving Emicizumab
-
Sep 5, 2025, 10:58Côme Bommier Recommends CRTH for Clinical Trial Training and Career Growth in Hematology